Role of topical chemotherapy for primary acquired melanosis and malignant melanoma of the conjunctiva and cornea: Review of the evidence and recommendations for treatment

Clinical and Experimental Ophthalmology

Volumn 34, Issue 7, 2006, Pages 708-714

  Chalasani, Rajeev ^a   Giblin, Michael ^a   Conway, R Max ^a  

^a SYDNEY EYE HOSPITAL   (Australia)

Author keywords

Conjunctiva; Cornea; Melanoma; Primary acquired melanosis; Topical chemotherapy

Indexed keywords

MITOMYCIN C;

CANCER LOCALIZATION; CLINICAL PRACTICE; CLINICAL TRIAL; CONJUNCTIVA DISEASE; CORNEA DISEASE; CORNEA LESION; CRYOTHERAPY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG USE; EPITHELIUM; EXCISION; EYE BIOPSY; EYELID EDEMA; FOLLOW UP; HUMAN; INFORMATION RETRIEVAL; KERATOCONJUNCTIVITIS; LACRIMAL DUCT OCCLUSION; MEDLINE; MELANOMA; MELANOSIS; METASTASIS; PANNUS; RECURRENT DISEASE; REVIEW; TISSUE INJURY;

ADMINISTRATION, TOPICAL; ANTIBIOTICS, ANTINEOPLASTIC; CONJUNCTIVAL NEOPLASMS; CORNEAL DISEASES; DATABASES, FACTUAL; EYE NEOPLASMS; HUMANS; MELANOMA; MELANOSIS; MITOMYCIN; PRACTICE GUIDELINES;

EID: 33748551970     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2006.01356.x     Document Type: Review

References (31)

1. Shields CL, Shields JA. Tumours of the conjunctiva and cornea. Surv Ophthalmol 2004; 49: 3-24.
2. Folberg R, McLean IW, Zimmerman LE. Primary acquired melanosis of the conjunctiva. Hum Pathol 1985; 16: 129-35.
3. Jakobiec FA, Folberg R, Iwamoto T. Clinicopathologic characteristics of premalignant and malignant melanocytic lesions of the conjunctiva. Ophthalmology 1989; 96: 147-66.
4. Layton C, Glasson W. Clinical aspects of conjunctival melanoma. Clin Experiment Ophthalmol 2002; 30: 72-9.
5. Folberg R, Mclean IW. Primary acquired melanosis and melanoma of the conjunctiva; terminology, classification and biologic behaviour. Hum Pathol 1986; 17: 652-4.
6. Seregard S. Conjunctival melanoma. Surv Ophthalmol 1998; 42: 321-50.
7. Brownstein S. Malignant melanoma of the conjunctiva. Cancer Control 2004; 11: 310-6.
8. Finger PT. Do you speak ocular tumor? Ophthalmology 2003; 110: 13-4.
9. Werschnik C. Lommatzsch. Long-term follow-up of patients with conjunctival melanoma. Am J Clin Oncol 2002; 25: 248-55.
10. Shields JA, Shields CL, De Potter P. Surgical management of circumscribed conjunctival melanomas. Ophthalmic Plast Reconstr Surg 1998; 14: 208-15.
11. Shields CL, Shields JA, Armstrong T. Management of conjunctival and corneal melanoma with surgical excision, amniotic membrane allograft, and topical chemotherapy. Am J Ophthalmol 2001; 132: 576-8.
12. Codere F, Brownstein S, Garwood JL, Dresner SC. Carbon dioxide laser treatment of the conjunctiva and cornea. Ophthalmology 1998; 95: 37-45.
13. Stannard CE, Sealy GRH, Herin ER, Pereira SB, Knowles R, Hill JC. Malignant melanoma of the eyelid and palpebral conjunctiva treated with iodine-125 brachytherapy. Ophthalmology 2000; 107: 951-8.
14. Paridaens AD, McCartney AC, Minassian DC, Hungerford JL. Orbital exenteration in 95 cases of primary conjunctival melanoma. Br J Ophthalmol 1994; 78: 520-8.
15. Basti S, Macsai MS. Ocular surface squamous neoplasia: A review. Cornea 2003; 22: 687-704.
16. Lommatzsch PK, Lommatzsch RE, Kirsch I, Fuhrmann P. Therapeutic outcome of patients suffering from malignant melanomas of the conjunctiva. Br J Ophthalmol 1990; 74: 615-9.
17. Jakobiec FA, Rini FJ, Fraunfelder FT, Brownstein S. Cryotherapy for conjunctival primary acquired melanosis and malignant melanoma. Experience with 62 cases. Ophthalmology 1988; 95: 1058-70.
18. Joseph A, Sabri K, Dua HS. Surgical excision, autolimbal transplantation, and mitomycin C in the treatment of conjunctival and corneal intraepithelial neoplasia. Br J Ophthalmol 2001; 85: 625.
19. Finger PT, Czechonska G, Liarikos S. Topical mitomycin C chemotherapy for conjunctival melanoma and PAM with atypia. Br J Ophthalmol 1998; 82: 476-9.
20. Frucht-Pery J, Pe'er J. Use of mitomycin C in the treatment of conjunctival primary acquired melanosis with atypia. Arch Ophthal 1996; 114: 1261-4.
21. Demirci H, McCormick SA, Finger PT. Topical mitomycin chemotherapy for conjunctival melanoma and primary acquired melanosis with atypia. Clinical experience with histopathological observations. Arch Ophthalmol 2000; 118: 885-91.
22. Finger PT, Milner MS, McCormick SA. Topical chemotherapy for conjunctival melanoma. Br J Ophthalmol 1993; 77: 751-3.
23. Rodriguez-Ares T, Tourino R, De Rojas V, Becerra E, Capeans C. Topical Mitomycin C in the treatment of pigmented conjunctival lesions. Cornea 2003; 22: 114-7.
24. Pe'er J, Frucht-Pery J. The treatment of primary acquired melanosis (PAM) with atypia by topical mitomycin C. Am J Ophthalmol 2005; 139: 229-34.
25. Kemp EG, Harnett AN, Chatterjee S. Preoperative topical and intraoperative local mitomycin C adjuvant therapy in the management of ocular surface neoplasias. Br J Ophthalmol 2002; 86: 31-4.
26. Kurli M, Finger PT. Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years' experience. Graefes Arch Clin Exp Ophthalmol 2005; 243: 1108-14.
27. Yuen VH, Jordan DR, Brownstein S, Dorey MW. Topical Mitomycin treatment for primary acquired melanosis of the conjunctiva. Ophthal Plast Reconstr Surg 2003; 19: 149-51.
28. De Potter P, Shields CL, Shields JA, Menduke H. Clinical predictive factors for development of recurrence and metastasis in conjunctival melanoma. a review of 68 cases. Br J Ophthalmol 1993; 77: 624-30.
29. Paridaens ADA, Minassian DC, McCartney ACE, Hungerford JL. Prognostic factors in primary malignant melanoma of the conjunctiva. a clinicopathological study of 256 cases. Br J Ophthalmol 1994; 78: 252-9.
30. Shields CL, Shields JA, Gunduz K etal. Conjunctival melanoma: Risk factors for recurrence, exenteration, metastasis and death in 150 consecutive patients. Arch Ophthalmol 2000; 118: 1497-507.
31. Dogru M, Erturk H, Shimazaki J, Tsubota K, Gul M. Tear function and ocular surface changes with topical mitomycin (MMC) treatment for primary corneal intraepithelial neoplasia. Cornea 2003; 22: 627-39.